SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus

Background: Laboratory diagnosis of SARS-CoV-2 infection (the cause of COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. SARS-CoV-2 RNA has also been detected in other sample types, but there is limited understanding of the clinical or laboratory significance of its detection in blood. Methods: We undertook a systematic literature review to assimilate the evidence for the frequency of vRNA in blood, and to identify associated clinical characteristics. We performed RT-PCR in serum samples from a UK clinical cohort of acute and convalescent COVID-19 cases (n=212), together with convalescent plasma samples collected by NHS Blood and Transplant (NHSBT) (n=212 additional samples). To determine whether PCR-positive blood samples could pose an infection risk, we attempted virus isolation from a subset of RNA-positive samples. Results: We identified 28 relevant studies, reporting SARS-CoV-2 RNA in 0-76% of blood samples; pooled estimate 10% (95%CI 5-18%). Among serum samples from our clinical cohort, 27/212 (12.7%) had SARS-CoV-2 RNA detected by RT-PCR. RNA detection occurred in samples up to day 20 post symptom onset, and was associated with more severe disease (multivariable odds ratio 7.5). Across clinical and convalescent samples collected [≥]28 days post symptom onset, 0/244 (0%, 95%CI 0.0-1.5%) had vRNA detected. Among our PCR-positive samples, cycle threshold (ct) values were high (range 33.5-44.8), suggesting low vRNA copy numbers. PCR-positive sera inoculated into cell culture did not produce any cytopathic effect or yield an increase in detectable SARS-CoV-2 RNA. Conclusions: vRNA was detectable at low viral loads in a minority of serum samples collected in acute infection, but was not associated with infectious SARS-CoV-2 (within the limitations of the assays used). This work helps to inform biosafety precautions for handling blood products from patients with current or previous COVID-19.

[1]  P. Simmonds,et al.  Evaluation of Different PCR Assay Formats for Sensitive and Specific Detection of SARS-CoV-2 RNA , 2020, bioRxiv.

[2]  J. Timsit,et al.  Immune alterations during SARS-CoV-2-related acute respiratory distress syndrome , 2020, medRxiv.

[3]  C. Cogliati,et al.  Viable circulating endothelial cells and their progenitors are increased in Covid-19 patients , 2020, medRxiv.

[4]  J. Zehnder,et al.  High Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease , 2020, medRxiv.

[5]  Zhiliang Gao,et al.  SARS‐CoV‐2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens , 2020, Journal of medical virology.

[6]  T. C. I. team.  Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States , 2020 .

[7]  Xia Yu,et al.  SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression , 2020, Critical Care.

[8]  T. Liang,et al.  Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study , 2020, BMJ.

[9]  N. Watkins,et al.  Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays , 2020, medRxiv.

[10]  Jianguo Wu,et al.  Detection and analysis of nucleic acid in various biological samples of COVID-19 patients , 2020, Travel Medicine and Infectious Disease.

[11]  Nan Tang,et al.  SARS-CoV-2 and viral sepsis: observations and hypotheses , 2020, The Lancet.

[12]  Namhee Kim,et al.  Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Michael Libman,et al.  Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus-2 , 2020, Annals of Internal Medicine.

[14]  H. Shan,et al.  Key to successful treatment of COVID-19: accurate identification of severe risks and early intervention of disease progression , 2020, medRxiv.

[15]  X. de Lamballerie,et al.  Evaluation of heating and chemical protocols for inactivating SARS-CoV-2 , 2020, bioRxiv.

[16]  Wei Zhang,et al.  Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19. , 2020, Viral immunology.

[17]  Lingjie Song,et al.  A case of SARS-CoV-2 carrier for 32 days with several times false negative nucleic acid tests , 2020, medRxiv.

[18]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[19]  Lan Wang,et al.  Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations , 2020, Emerging infectious diseases.

[20]  A. Tam,et al.  Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis , 2020, Gastroenterology.

[21]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[22]  S. Ciesek,et al.  SARS‐CoV‐2 asymptomatic and symptomatic patients and risk for transfusion transmission , 2020, medRxiv.

[23]  W. Cai,et al.  SARS-CoV-2 detection using digital PCR for COVID-19 diagnosis, treatment monitoring and criteria for discharge , 2020, medRxiv.

[24]  Nan Wang,et al.  Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Xavier Duval,et al.  Clinical and virological data of the first cases of COVID-19 in Europe: a case series , 2020, The Lancet Infectious Diseases.

[26]  Guohong Deng,et al.  Viral Kinetics and Antibody Responses in Patients with COVID-19 , 2020, medRxiv.

[27]  Wenhong Zhang,et al.  Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients , 2020, Journal of Infection.

[28]  Huiying Liang,et al.  Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding , 2020, Nature Medicine.

[29]  R. Lu,et al.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens. , 2020, JAMA.

[30]  Dong Men,et al.  Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients , 2020, medRxiv.

[31]  J. Low,et al.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.

[32]  Yixiao Lin,et al.  Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients , 2020, Chinese medical journal.

[33]  Xiangshi Wang,et al.  A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Lingxi Jiang,et al.  Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests , 2020, International Journal of Infectious Diseases.

[35]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[36]  Feng Li,et al.  Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity , 2020, Emerging microbes & infections.

[37]  Wei Zhang,et al.  Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes , 2020, Emerging microbes & infections.

[38]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[39]  F. Suter-Riniker,et al.  Effective chemical virus inactivation of patient serum compatible with accurate serodiagnosis of infections , 2018, Clinical Microbiology and Infection.

[40]  D. Marks,et al.  The impact on blood donor screening for human immunodeficiency virus, hepatitis C virus, and hepatitis B virus using plasma from frozen‐thawed plasma preparation tubes , 2016, Transfusion.

[41]  P. Simmonds,et al.  Development and Assay of RNA Transcripts of Enterovirus Species A to D, Rhinovirus Species A to C, and Human Parechovirus: Assessment of Assay Sensitivity and Specificity of Real-Time Screening and Typing Methods , 2012 .

[42]  H. Too,et al.  Evaluation of pre-analytical variables in the quantification of dengue virus by real-time polymerase chain reaction. , 2009, The Journal of molecular diagnostics : JMD.

[43]  J. S. Porterfield,et al.  A simple micro-culture method for the study of group B arboviruses. , 1969, Bulletin of the World Health Organization.